Article ; Online: EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age.
Therapeutic innovation & regulatory science
2023 Volume 57, Issue 4, Page(s) 656–661
Abstract: As medicines development continues towards a globalized approach, both the pharmaceutical industry and regulatory agencies increasingly seek opportunities to proactively engage early in product development. The parallel scientific advice program shared ... ...
Abstract | As medicines development continues towards a globalized approach, both the pharmaceutical industry and regulatory agencies increasingly seek opportunities to proactively engage early in product development. The parallel scientific advice program shared by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) provides a mechanism for experts to concurrently engage in scientific discourse with sponsors on key issues during the development phase of new medicinal products (drugs, biologicals, vaccines, and advanced therapies). |
---|---|
MeSH term(s) | United States ; United States Food and Drug Administration ; Biological Products ; Government Agencies ; Medicine ; Drug Industry |
Chemical Substances | Biological Products |
Language | English |
Publishing date | 2023-03-04 |
Publishing country | Switzerland |
Document type | Journal Article |
ZDB-ID | 2708397-4 |
ISSN | 2168-4804 ; 2168-4790 |
ISSN (online) | 2168-4804 |
ISSN | 2168-4790 |
DOI | 10.1007/s43441-023-00501-9 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.